Home
Publication
Commentaries
Brochure on the genO-BRGSF mouse model

Brochure on the genO-BRGSF mouse model

15 min read
December 18, 2025

Download the brochure to learn more about genO-BRGSF:

  • The genO-BRGSF mouse strain is an immunocompromised mouse model ideal for oncology and immunology studies.
  • Its genetic profile, combining Rag2, IL2Rγ, SIRPα and FLT3 mutations, creates an environment highly permissive to human cell engraftment, including CDX, PDX, and PBMCs.
  • With a functional complement system, extended lifespan, and resistance to radiation-induced damage, genO-BRGSF offers a stable and reliable platform for investigating tumour biology, metastasis, and therapeutic interventions such as chemotherapy, immunotherapy, and cell-based treatments.
  • Explore the brochure to learn how the genO-BRGSF can enhance the predictability and translational value of your research.

‍

Related products

Catalogue product

genO-BRGSF

The genO-BRGSF mouse is the most immunodeficient model developed so far, relative to strains like NOD-SCID and NSG.

Customized product

No items found.
Other commentaries
Role of hFlt3L in the development of myeloid and dendritic cells in genO‑BRGSF‑HIS mice

Role of hFlt3L in genO-BRGSF-HIS mice

10 min read
-
Oct 2025
Development of a new antibody-drug conjugate against CD71, INA03, for the treatment of leukemia

TFRC for anti-cancer therapies

8 min read
-
Jul 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

8 min read
-
Apr 2024
BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

BRGSF-HIS as model for acute implant-associated osteomyelitis

10 min read
-
Apr 2024
Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

10 min read
-
Mar 2024
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized genO-BRGSF-HIS preclinical model

CRS in genO-BRGSF-HIS

7 min read
-
Feb 2024
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

10 min read
-
Dec 2023
Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Myeloid compartment in BRGSF-HIS

7 min read
-
Dec 2023
Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

3 min read
-
Oct 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

9 min read
-
Jun 2023
Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

3 min read
-
Mar 2023
An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

3 min read
-
Nov 2022
Functional human myeloid compartment in BRGSF-HIS preclinical model

Myeloid compartment in BRGSF-HIS

4 min read
-
Nov 2022
A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

10 min read
-
Jul 2022
Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

6 min read
-
Jun 2022
Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Myeloid compartment in BRGSF-HIS

6 min read
-
Jun 2022
Challenging the predictability of preclinical models for assessment of T-cell engagers

Assess T-cell engager in BRGSF-HIS

5 min read
-
May 2022
Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Myeloid compartment in immuno-oncology

3 min read
-
Apr 2022
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

3 min read
-
Mar 2022
An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

4 min read
-
Mar 2022
Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

5 min read
-
Mar 2022
Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

8 min read
-
Jan 2022
Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Engraftments in BRGSF-HIS

8 min read
-
Nov 2021
NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

Customized mouse model

3 min read
-
Nov 2021
A human-specific modifier of cortical connectivity and circuit function

Customized mouse model

3 min read
-
Nov 2021
Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

PDX in BRGSF-HIS

6 min read
-
Nov 2021
Cytokine release syndrome (CRS)

Assess T-cell engager in BRGSF-HIS

5 min read
-
Sep 2021
The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

4 min read
-
Sep 2021
Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Immunotherapy in BRGSF-HIS

6 min read
-
Aug 2021
Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Tumor-graft models

5 min read
-
Aug 2021
New doors to potential novel treatments for obesity

Customized mouse model

3 min read
-
Jun 2021
Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

5 min read
-
Apr 2021
Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

5 min read
-
Apr 2021
Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

3 min read
-
Apr 2021
A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

8 min read
-
Feb 2021
Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

4 min read
-
Nov 2020
HSA/hFcRn, a powerful model for your PK/PD studies

Immuno-oncolology models

6 min read
-
Jul 2020
Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

Immuno-oncolology models

15 min read
-
May 2020
A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Customized mouse model

3 min read
-
Apr 2020
Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies

Immuno-oncolology models

6 min read
-
Apr 2020
Syngeneic mouse models

Customized mouse model

3 min read
-
Apr 2020
Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

Immuno-oncolology models

6 min read
-
Mar 2020
HSC-derived cell fate tracking

Customized mouse model

3 min read
-
Mar 2020
A VISTA on naive T cell fate

Humanized ICP mouse

3 min read
-
Feb 2020
Part 1:  Toward a better effective preclinical model in immuno-oncology

Immuno-oncolology models

10 min read
-
Jan 2020
A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

Customized mouse model

3 min read
-
Jan 2020
A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

3 min read
-
Oct 2019
6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Eucomm conditional Knockouts

6 min read
-
Aug 2019
Immune checkpoint inhibitors: A strategy to tackle cancer?

Immuno-oncology models (ICP)

3 min read
-
Jul 2019
Show all commentaries
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe

Mouse
Immuno-Oncology
BRGSF